StockNews.com Initiates Coverage on Trinity Biotech (NASDAQ:TRIB)

Equities researchers at StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research report issued to clients and investors on Sunday. The brokerage set a “buy” rating on the stock.

Trinity Biotech Trading Down 3.0 %

Trinity Biotech stock opened at $3.20 on Friday. The firm has a 50 day moving average of $2.24 and a 200 day moving average of $2.20. The firm has a market capitalization of $24.38 million, a price-to-earnings ratio of -1.15 and a beta of 1.31. Trinity Biotech has a 12-month low of $1.49 and a 12-month high of $5.25.

Trinity Biotech (NASDAQ:TRIB) last announced its quarterly earnings data on Thursday, May 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter. The business had revenue of $14.70 million for the quarter. On average, analysts predict that Trinity Biotech will post -2.17 EPS for the current year.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.